Biorestorative Therapies, Inc. (BRTX) vs Lipella Pharmaceuticals Inc. (LIPO)

Biorestorative Therapies, Inc. and Lipella Pharmaceuticals Inc. are both Biotechnology companies. Biorestorative Therapies, Inc. and Lipella Pharmaceuticals Inc. are of similar size ($3.5M and $3.4M). Lipella Pharmaceuticals Inc. grew revenue faster over the last twelve months: −7.29% against −8.47%. Lipella Pharmaceuticals Inc. has the higher net margin (0.00% vs −3,089.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Lipella Pharmaceuticals Inc. leads on 10 and Biorestorative Therapies, Inc. on 5.

Valuation

Metric BRTX LIPO Biotechnology median
P/E n/m n/m 7.88
P/S 6.32 n/m 11.47
P/B 0.75 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.09 0.31 0.74
EV/Sales (3.60) (3.61) 10.73
Earnings yield (839.22%) 0.00% (28.84%)
Free cash flow yield (579.97%) 0.00% (23.03%)

Profitability

Metric BRTX LIPO Biotechnology median
Gross margin 92.09% 100.00% 65.16%
Operating margin (3,974.66%) 0.00% 0.00%
Net margin (3,089.30%) 0.00% 0.00%
Free cash flow margin (3,302.04%) 0.00% 0.00%
Return on equity (241.50%) (361.77%) (57.72%)
Return on assets (147.75%) (236.36%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BRTX LIPO Biotechnology median
Revenue growth (TTM) (8.47%) (7.29%) 5.64%
EPS growth (last fiscal year) (36.21%) 22.24% —
Revenue growth, 5-year CAGR 36.11% (5.04%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BRTX LIPO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.35 3.24 4.73
Net debt to EBITDA 0.19 0.43 0.96

Dividend

Metric BRTX LIPO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric BRTX LIPO Biotechnology median
Market cap 3.47m 3.39m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack